Trends in Cardiovascular Medicine最新文献_第2页

Unexplained sudden cardiac arrest and sudden cardiac death in the young: What is killing these young people when nothing is found? 年轻人不明原因的心脏骤停和心脏性猝死：在没有任何发现的情况下，是什么夺走了这些年轻人的生命？

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-04-01 DOI: 10.1016/j.tcm.2024.11.002

Andrew S. Tseng , Mayank Sardana , John R. Giudicessi , Michael J. Ackerman

{"title":"Unexplained sudden cardiac arrest and sudden cardiac death in the young: What is killing these young people when nothing is found?","authors":"Andrew S. Tseng , Mayank Sardana , John R. Giudicessi , Michael J. Ackerman","doi":"10.1016/j.tcm.2024.11.002","DOIUrl":"10.1016/j.tcm.2024.11.002","url":null,"abstract":"<div><div>Unexplained sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in the young remains a critical issue for clinicians, researchers, patients and their family members. In this review, we explore the current status of SCA and SCD evaluation in the young, including recent monogenic and polygenic disease discoveries, advancements in cardiac imaging and our growing understanding of the role of the Purkinje system in triggering life threatening and even fatal ventricular arrhythmias. Yet, despite these advancements, over a third of SCA and SCD among individuals with seemingly structurally normal hearts remain unexplained. We explore the future role of artificial intelligence, novel biomarkers, multimodality cardiac imaging, genetic discoveries, as well as wearable devices and sensors in closing this current gap. With the overarching framework provided in this review, we envision a future in which collaboration among patients, clinicians, researchers, innovators, and policy makers culminates in our ability to diagnose, predict, and ultimately prevent SCA and SCD in the young.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 3","pages":"Pages 177-183"},"PeriodicalIF":7.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial commentary: The birth and growth of Cardio-Obstetrics: Managing cardiovascular risk and disease in pregnancy 心脏产科的出生和成长：管理妊娠期心血管风险和疾病。

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-04-01 DOI: 10.1016/j.tcm.2024.11.003

Yuliya Krokhaleva, Marmar Vaseghi

引用次数: 0

Happy heart syndrome – The impact of different triggers on the characteristics of takotsubo syndrome 快乐心综合征：不同触发因素对Takotsubo综合征特征的影响。

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-04-01 DOI: 10.1016/j.tcm.2024.12.002

Thomas Stiermaier, Ingo Eitel

引用次数: 0

Technological interventions to address cardiovascular health disparities impacting racial minorities: Opportunities and challenges.

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-03-30 DOI: 10.1016/j.tcm.2025.03.005

Audrey Todd, Carl J Lavie, Shady Abohashem

引用次数: 0

Impact of medical versus surgical weight loss on cardiovascular outcomes.

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-03-28 DOI: 10.1016/j.tcm.2025.03.004

Alexander Ostapenko, Bestoun Ahmed

{"title":"Impact of medical versus surgical weight loss on cardiovascular outcomes.","authors":"Alexander Ostapenko, Bestoun Ahmed","doi":"10.1016/j.tcm.2025.03.004","DOIUrl":"https://doi.org/10.1016/j.tcm.2025.03.004","url":null,"abstract":"<p><p>Obesity contributes to cardiovascular disease in two ways - directly, as an independent risk factor, and indirectly, through its contribution to comorbidities such as hypertension, diabetes, dyslipidemia. This cascade of multiplicative effects means that early management of obesity is instrumental in risk reduction and prevention of adverse cardiovascular outcomes. The amount and sustainability of weight loss has been extensively studied and stratified by medical versus surgical weight loss. Medical weight loss has historically been inferior by both parameters; however, new therapies targeting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors have demonstrated very promising results independently for both weight loss and cardiovascular disease. In this review, we compare cardiovascular outcomes between bariatric surgical approaches and novel GLP-1/GIP medications. We aim to answer the following question: In this era of new pharmacological weight loss options, does the method of weight loss-surgical or medical-impact cardiovascular risk mitigation, or is the key factor the maintenance of a healthier weight, regardless of the method?</p>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in the screening, diagnosis, and treatment of transthyretin amyloid cardiomyopathy: New insights and future directions. 转甲状腺素淀粉样变性心肌病的筛查、诊断和治疗进展：新见解和未来方向。

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-03-25 DOI: 10.1016/j.tcm.2025.03.002

Andrew A Girard, Talal Asif, Brett W Sperry

{"title":"Advances in the screening, diagnosis, and treatment of transthyretin amyloid cardiomyopathy: New insights and future directions.","authors":"Andrew A Girard, Talal Asif, Brett W Sperry","doi":"10.1016/j.tcm.2025.03.002","DOIUrl":"10.1016/j.tcm.2025.03.002","url":null,"abstract":"<p><p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive form of heart failure caused by myocardial tissue infiltration with fibrillar amyloid deposits. ATTR-CM has been traditionally underrecognized and regarded by clinicians as a challenging condition to manage, owing to limited availability of effective screening methods, diagnostic testing, and therapeutic options. More recently, multiple clinical trials have emerged evaluating the efficacy of novel pharmacologic therapies which target amyloid generation and pre-existing amyloid deposits. Results reveal robust treatment benefits in function and survival, offering clinicians and patients new therapeutics which alter the clinical trajectory of ATTR-CM. Importantly, the benefits of treatment with these therapies appear to be more pronounced when initiated at an early stage of disease. As a result, a renewed interest in the early detection of ATTR-CM has developed, with efforts currently underway to promote increased disease awareness and enhance diagnosis through standardized screening algorithms and advanced imaging techniques. This review will provide an in-depth description of the advancements in ATTR-CM screening, diagnosis, and treatment that are currently available for implementation in routine care. Furthermore, we highlight several investigational modalities on the horizon for ATTR-CM with a particular focus on their potential roles in future clinical practice.</p>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143732972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary use of non transvenous ICD.

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-03-17 DOI: 10.1016/j.tcm.2025.03.003

Ayesha Shaik, Theofanie Mela

引用次数: 0

Management of angina pectoris.

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-03-12 DOI: 10.1016/j.tcm.2025.03.001

Riccardo Rinaldi, Vijay Kunadian, Filippo Crea, Rocco A Montone

{"title":"Management of angina pectoris.","authors":"Riccardo Rinaldi, Vijay Kunadian, Filippo Crea, Rocco A Montone","doi":"10.1016/j.tcm.2025.03.001","DOIUrl":"10.1016/j.tcm.2025.03.001","url":null,"abstract":"<p><p>Angina pectoris, a primary manifestation of ischemic heart disease, imposes a significant clinical and economic burden globally. This review highlights recent advancements in the management of angina, emphasizing a patient-centred approach that integrates pharmacological, interventional, and lifestyle strategies to reduce cardiovascular risk and improve patient outcomes. For obstructive coronary artery disease, optimal medical therapy represents the cornerstone of treatment. Individualized regimens should be tailored to clinical factors such as blood pressure, heart rate, left ventricular function, comorbidities like heart failure and diabetes, concomitant medications, patient preferences, and drug availability. Myocardial revascularization is reserved for select cases to alleviate symptoms or improve prognosis. For angina or ischemia with non-obstructive coronary arteries (ANOCA/INOCA), precise endotype classification, differentiating microvascular angina, vasospastic angina, mixed type and non-coronary chest pain, enables personalized treatment strategies. Lifestyle interventions, including smoking cessation, weight management, adherence to Mediterranean diet, and exercise therapy, are essential components of care, promoting improved cardiovascular outcomes and quality of life. Structured exercise programs, particularly within cardiac rehabilitation settings, have demonstrated efficacy in enhancing functional capacity and reducing adverse events. Emerging therapies, including pharmacological agents and novel interventional approaches such as the coronary sinus reducer, hold promise for addressing unmet needs in refractory angina and challenging ANOCA/INOCA cases. Future directions should prioritize the integration of precision medicine, digital health technologies, and multidisciplinary care to optimize outcomes and advance personalized angina management.</p>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143631051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atrial fibrillation in patients with cardiomyopathy - Protecting the vulnerable.

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-03-11 DOI: 10.1016/j.tcm.2025.02.011

James W Salazar, Daniel P Morin

引用次数: 0

Advancing our understanding of cardiac tumors.

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-03-07 DOI: 10.1016/j.tcm.2025.02.010

Massimo Imazio

引用次数: 0